Beam Therapeutics Inc.
BEAM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001745999
In the last 90 days, Beam Therapeutics Inc. insiders filed 0 open-market purchases and 1 sale; 277 institutions reported holding it in 13F filings for Q2 2026, worth $3.75B in total; superinvestors ARK Invest and Duquesne Family Office hold it.
Q2 2021 vs. Q1 2021
How the institutions holding Beam Therapeutics Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 210 | 231 | +21 |
| Shares | 43.0M | 45.5M | +2.47M (+5.7%) |
| Value | $3.44B | $5.85B | +$2.42B (+70.3%) |
New holders (56)
Institutions that held Beam Therapeutics Inc. at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (35)
Institutions that held Beam Therapeutics Inc. at the end of Q1 2021 and filed for Q2 2021 without it.